| Page 1797 | Kisaco Research
 
Phage Futures Europe
23-24 Nov 2021
Brussels, Belgium
Join us for the return of Phage Futures Europe, this November 2021 in Brussels, as we continue all-important discussions on translating new phage-based applications into clinical studies and beyond. Network and learn from multinational pharma, emerging biotechs, leading academics, investment representatives and regulatory bodies to discover how you can be at the forefront of the developing phage therapy market.Introducing face-to-face interactions once again, Phage Futures Europe will help you maximise networking and commercial development with key industry players such as GSK, BiomX, Contrafect and more. This year, we discuss the viability of phage derived lysines in therapy, assess the therapeutic application of natural phages vs engineered phages and explore the clinical data surrounding the magisterial and compassionate use of phages in Europe. Bacteriophages have seen continued investment and have adapted to global challenges, introducing commercial and marketable prospects for phage application. Phage Futures Europe explores the commercial applications of phages in poultry, aquaculture, biocontrol and skin microbiome, providing insights into the global design of phage products and acquiring pharmaceutical partnerships.
Visit Site
 

Christopher Mason

Weill Cornell Medicine

Christopher Mason

Weill Cornell Medicine

Christopher Mason

Weill Cornell Medicine
 
Phage Futures 2021
24-26 Feb 2021
Virtual Congress
Join us at the International Phage Futures Congress in 2021, as we create a virtual stage upon which to initiate all-important discussions & forge partnerships between key stakeholders from all over the world. Experts in their respective fields will discuss how to translate new phage-based applications into clinical studies & beyond.Discover how you can be at the forefront of the developing phage therapy market.Network & learn from established biotech companies, emerging start-ups, leading academics, global accelerator representatives, investment firms, international healthcare organisations & regulatory bodies. Among other topics, expect to hear & participate in:Advice on how to successfully navigate clinical trial progression to prove efficacy along with recent developments from leading biotechs in phage therapeutic trials targeting chronic & acute illnesses.Regulatory discussions between international governing bodies with region specific follow-up conversations with the experts.Insights into new fields for phage application, such as oncology, diagnostics & microbial gene therapy.Expert advice on how to find & secure financial investments.
Visit Site
Europe Pet Industry Primer
 
Skin Microbiome EU 2019
13-14 Nov 2019
London, United Kingdom
With 2.35 billion Euros being spent on cosmetic product R&D in Europe, are you ready for the next generation of skin care?Skin Microbiome continues it's reign as the 'biggest skincare trend' of the last two years, according to major market researchers and beauty bibles alike.  This year, we present the first dual-track, data-focused skin microbiome congress:Data Track: focuses on the hard data that supports and legitmises product and research claims while driving increased understanding of the skin microbiome.Commercial Track: tackles the challenges faced when building a commercially viable skin microbiome company, optimising your supply chain and executing successful communication strategies.Discover the potential of prebiotic, probiotic and postbiotic products being developed to protect and promote a healthy microbiome and ultimately combat dermatological conditions from acne and eczema to dandruff and skin allergies. Don't miss your chance to understand the next generation of skincare products!
Visit Site
 

Brian Burke

Head of Strategy
Horizon Discovery

Brian joined Horizon in 2012 during which time he has led various functions including Sales, Business Development and Product Management.  Much of his career has been focused in driving both the NGS and gene editing revolutions, most notably in the fields of diagnostics and bioprocessing.  In 2018 he was promoted to the Global Head of Strategy and now leads Horizon’s Corporate Development efforts including strategy development and M&A. 

Read full bio

Brian Burke

Head of Strategy
Horizon Discovery

Brian Burke

Head of Strategy
Horizon Discovery

Brian joined Horizon in 2012 during which time he has led various functions including Sales, Business Development and Product Management.  Much of his career has been focused in driving both the NGS and gene editing revolutions, most notably in the fields of diagnostics and bioprocessing.  In 2018 he was promoted to the Global Head of Strategy and now leads Horizon’s Corporate Development efforts including strategy development and M&A. 

 

Bruno Cluzel

Executive Director, International Operations, Diagnostics Customer Care
Zoetis

Bruno Cluzel is Executive Director, International Operations, Diagnostics Customer Care for Zoetis. In this role, he is responsible to define guidelines for customer and technical support services delivered in the markets; deliver elevated technical support and instrument repair; provide guidance to the Diagnostic Application Specialists in-market technical support; and develop and help deliver training curriculum, materials and sessions.

Read full bio

Bruno Cluzel

Executive Director, International Operations, Diagnostics Customer Care
Zoetis

Bruno Cluzel

Executive Director, International Operations, Diagnostics Customer Care
Zoetis

Bruno Cluzel is Executive Director, International Operations, Diagnostics Customer Care for Zoetis. In this role, he is responsible to define guidelines for customer and technical support services delivered in the markets; deliver elevated technical support and instrument repair; provide guidance to the Diagnostic Application Specialists in-market technical support; and develop and help deliver training curriculum, materials and sessions.

Bruno has extensive experience working within the animal health care sector. Through his career, Bruno has held various roles working across a number of different functions and regions.  

With a passion for animal health, Bruno holds a diploma of Veterinary Medicine and started his career as a Practitioner specialized in Production Animal with a focus on Avian Medicine. After 15 years in this role, he joined Merial where he had different roles across Europe Africa and Middle East: technical, marketing and business lead. He joined Pfizer Animal Health in 2011 to help entering the Diagnostics. In his current role, he is building Customer Care capabilities as Zoetis expands around the Globe.

 

Dr. Julie Horvath

Head of the Genomics & Microbiology Research Lab at the North Carolina Museum of Natural Sciences AND jointly appointed Research Associate Professor at North Carolina Central University
North Carolina Central University

Dr. Julie Horvath is a comparative evolutionary genomicist interested in understanding the evolutionary forces that have shaped primate genomes and that cause human disease. Genetic and genomic comparisons between humans and our closest relatives, the primates, are crucial for understanding our own evolution and unique characteristics. The foundation of Dr. Horvath’s research is based on species relationships, or phylogenies, which she first established for lemurs, and more recently, for all primates. These species relationships are applied to many of her research questions.

Read full bio

Dr. Julie Horvath

Head of the Genomics & Microbiology Research Lab at the North Carolina Museum of Natural Sciences AND jointly appointed Research Associate Professor at North Carolina Central University
North Carolina Central University

Dr. Julie Horvath

Head of the Genomics & Microbiology Research Lab at the North Carolina Museum of Natural Sciences AND jointly appointed Research Associate Professor at North Carolina Central University
North Carolina Central University

Dr. Julie Horvath is a comparative evolutionary genomicist interested in understanding the evolutionary forces that have shaped primate genomes and that cause human disease. Genetic and genomic comparisons between humans and our closest relatives, the primates, are crucial for understanding our own evolution and unique characteristics. The foundation of Dr. Horvath’s research is based on species relationships, or phylogenies, which she first established for lemurs, and more recently, for all primates. These species relationships are applied to many of her research questions. Several examples of Horvath’s research investigate the connection between genotype (DNA sequence) and phenotype (traits and characteristics) that make flora and fauna unique. 

 

Jonathan Gilbert

Global Commercial Lead Microbiome GI Health
Nestlé Health Science

Jonathan Gilbert

Global Commercial Lead Microbiome GI Health
Nestlé Health Science

Jonathan Gilbert

Global Commercial Lead Microbiome GI Health
Nestlé Health Science
 

Craig Thomson

Partner & Patent Attorney
HGF Limited

Craig has considerable experience in providing pragmatic, commercially focused advice to a wide-range of clients and in relation to biotechnological and pharmaceutical fields.  As well as patent drafting and prosecution, Craig advises on the development of company-wide IP strategies, preparing for or carrying out funding/acquisition due diligence, and advising on aggressive/defensive strategies in relation to third party IP. He has a particular interest in inventions relating to the microbiome, including bacteriophage.

Read full bio

Craig Thomson

Partner & Patent Attorney
HGF Limited

Craig Thomson

Partner & Patent Attorney
HGF Limited

Craig has considerable experience in providing pragmatic, commercially focused advice to a wide-range of clients and in relation to biotechnological and pharmaceutical fields.  As well as patent drafting and prosecution, Craig advises on the development of company-wide IP strategies, preparing for or carrying out funding/acquisition due diligence, and advising on aggressive/defensive strategies in relation to third party IP. He has a particular interest in inventions relating to the microbiome, including bacteriophage.